BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, May 14, 2024
See today's BioWorld
Home
» Following in-depth therapeutic review, Mogrify adds $17M to series A
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Following in-depth therapeutic review, Mogrify adds $17M to series A
May 4, 2021
By
Nuala Moran
No Comments
LONDON – Cell transdifferentiation specialist Mogrify Ltd. has raised $17 million in the second close its series A, taking the round to $33 million and enabling the company to progress three cell therapy programs to the clinic.
BioWorld
Financings
Cell therapy
Series A